TipRanks
MetaVia (MTVA)
NASDAQ:MTVA
US Market
MTVA
MetaVia
RESEARCH TOOLSreports
Want to see MTVA full AI Analyst Report?

MetaVia (MTVA) Stock News & Sentiment

505 Followers
Analyst Maintains Buy Rating on MetaVia (MTVA) with Unchanged $8 Price Target, Citing Strong Early Obesity Data for DA-1726
Premium
Ratings
Analyst Maintains Buy Rating on MetaVia (MTVA) with Unchanged $8 Price Target, Citing Strong Early Obesity Data for DA-1726
21d ago
MTVA
MetaVia Highlights DA-1726 Preclinical Data for Obesity Program
Premium
Company Announcements
MetaVia Highlights DA-1726 Preclinical Data for Obesity Program
22d ago
8K
MTVA
MetaVia (MTVA): Buy Rating Reiterated as DA-1726 Nears Key 4Q26 Data; $20 Price Target Reaffirmed
Premium
Ratings
MetaVia (MTVA): Buy Rating Reiterated as DA-1726 Nears Key 4Q26 Data; $20 Price Target Reaffirmed
2M ago
MTVA
MetaVia Advances DA-1726 and Vanoglipel in Q2 Update
Premium
Company Announcements
MetaVia Advances DA-1726 and Vanoglipel in Q2 Update
2M ago
8K
MTVA
Analyst Maintains Buy on MetaVia, Keeps $8 Price Target as DA-1726 Next-Gen Obesity Data Advances
Premium
Ratings
Analyst Maintains Buy on MetaVia, Keeps $8 Price Target as DA-1726 Next-Gen Obesity Data Advances
3M ago
MTVA
Analyst Reaffirms Buy on MTVA as DA-1726 Data De-Risk Obesity and MASH Opportunity; Price Target Maintained at $20
Premium
Ratings
Analyst Reaffirms Buy on MTVA as DA-1726 Data De-Risk Obesity and MASH Opportunity; Price Target Maintained at $20
3M ago
MTVA
MetaVia Advances DA-1726 Obesity Trial to Top Doses
Premium
Company Announcements
MetaVia Advances DA-1726 Obesity Trial to Top Doses
3M ago
8K
MTVA
More MTVA News >

MTVA News on the Web

Analyst Maintains Buy Rating on MetaVia (MTVA) with Unchanged $8 Price Target, Citing Strong Early Obesity Data for DA-1726
TipRanks News
Bullish
Analyst Maintains Buy on MetaVia, Keeps $8 Price Target as DA-1726 Next-Gen Obesity Data Advances
TipRanks News
Bullish
Analyst Reaffirms Buy on MTVA as DA-1726 Data De-Risk Obesity and MASH Opportunity; Price Target Maintained at $20
TipRanks News
Bullish
MetaVia Advances DA-1726 Obesity Trial to Top Doses
TipRanks News
Neutral
MetaVia announces completion of dose titration in Phase 1 study of DA-1726
TipRanks News
Bullish
MetaVia Announces $4 Million At-The-Market Stock Offering
TipRanks News
Neutral
MetaVia: Buy Rating Reiterated as Synergistic Cardiometabolic Pipeline Supports Unchanged $8 Price Target
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: MetaVia (MTVA) and Adlai Nortye Ltd. Sponsored ADR (ANL)
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0.75 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MTVA’s Media Buzz Sentiment?
Currently, no data Available
What is MTVA’s weekly average amount of articles?
In an average week, 0.75 articles about MTVA are published.
    What is MTVA’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    SMMTSummit Therapeutics
    CDNACareDx
    ARGXArgenx Se
    MEOBFMesoblast Limited
    KODKodiak Sciences
    Showing the stocks with the most bullish news sentiment over the past week